KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Accured Expenses (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Change in Accured Expenses for 4 consecutive years, with $21.7 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Change in Accured Expenses rose 190.5% year-over-year to $21.7 million, compared with a TTM value of $16.9 million through Dec 2023, up 142.63%, and an annual FY2025 reading of $10.4 million, up 125.66% over the prior year.
  • Change in Accured Expenses was $21.7 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$818000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $21.7 million in Q4 2023 and bottomed at -$24.0 million in Q4 2022.
  • Average Change in Accured Expenses over 4 years is $2.2 million, with a median of $7.0 million recorded in 2020.
  • The sharpest move saw Change in Accured Expenses tumbled 1080.02% in 2022, then skyrocketed 190.5% in 2023.
  • Year by year, Change in Accured Expenses stood at $7.0 million in 2020, then surged by 117.88% to $15.2 million in 2021, then plummeted by 257.94% to -$24.0 million in 2022, then surged by 190.5% to $21.7 million in 2023.
  • Business Quant data shows Change in Accured Expenses for DNA at $21.7 million in Q4 2023, -$818000.0 in Q3 2023, and -$23.1 million in Q2 2023.